Addex Therapeutics Financials - Benzinga

Addex Therapeutics Ltd

ADXNNASDAQ

Trade with Public

Trade with Public

$3.65

-0.06-1.62%

At close: Sep 4, 5:00 PM EST

$3.72

0.071.92%

After Hours: 8:07 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Stock Report

Addex Therapeutics Financials

Addex Therapeutics (ADXN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Earnings Scheduled For June 25, 2026

Companies Reporting Before The Bell • TD Synnex (NYSE:SNX) is projected to report quarterly earnings at $4.10 per share on revenue of $16.79 billion. • Yiren Digital (NYSE:YRD) is estimated to report earnings for its

Benzinga Insights

PRO
Addex Therapeutics Q1 EPS $(1.53) Down From $(1.33) YoY, Sales $10.214K Down From $78.928K YoY

Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.53) per share. This is a 15.04 percent decrease over losses of $(1.33) per share from the same period last year. The company reported $10.214 thousand

Benzinga Newsdesk

PRO
Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M

Basic and diluted loss per share remained stable at CHF 0.01 per share for the three-month periods ended March 31, 2026 and 2025.

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

PRO
Addex Therapeutics Q4 EPS $(1.50) Down From $(1.37) YoY, Sales $20.020K Up From $1.719K YoY

Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.50) per share. This is a 9.49 percent decrease over losses of $(1.37) per share from the same period last year. The company reported $20.020 thousand in

Benzinga Newsdesk

PRO
Addex Closes 2025 With CHF 6.7M Net Loss And CHF 1.6M Cash, Regains ADX71149 Rights And Invests In Stalicla

Benzinga Newsdesk